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Challenges in Using Opioids to Treat Pain in Persons With Substance 
Use Disorders 
P
ain and substance abuse co-occur frequently, and each can make the other more difficult to treat. A knowledge of pain and 
its interrelationships with addiction enhances the addiction specialist’s efficacy with many patients, both in the substance 
abuse setting and in collaboration with pain specialists. This article discusses the neurobiology and clinical presentation of 
pain and its synergies with substance use disorders, presents methodical approaches to the evaluation and treatment of pain 
that co-occurs with substance use disorders, and provides practical guidelines for the use of opioids to treat pain in individuals 
with histories of addiction. The authors consider that every pain complaint deserves careful investigation and every patient 
in pain has a right to effective treatment. 
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INTRODUCTION 
P
ain is integral to life; it is a critical component of the body’s natural defense 
system, signaling threats to body integrity and provoking self-preserva­
tion behaviors to further survival. Because pain often signals an urgent 
need to act (e.g., to flee, strike back, or otherwise respond aggressively to a threat), 
significant pain is typically associated with strong feelings (e.g., combinations 
of fear, anxiety, anger, or rage). Pain also sometimes occurs in the absence of any 
discernible threat or identifiable tissue damage, due to alterations in normal neu­
ral processing. It is not uncommon, therefore, to encounter distressed patients 
complaining of pain for which the origin is elusive. 
When pain is complicated by a co-occurring addictive disorder, particularly 
in a patient using opioids for pain control, evaluation and treatment may present 
a complex clinical challenge to care providers and generate considerable frustra­
tion and prolonged suffering for the patient. In this as in other contexts, all com­
plaints of pain must be taken seriously and carefully evaluated, because pain alone 
can impair health, function, and quality of life. Addiction professionals can con­
tribute valuable perspective and skills to the care of these patients, and more so if 
they possess a working understanding of pain’s mechanisms, evaluation and man­
agement, and interrelationships with substance use. 
The Prevalence of Pain 
Virtually everyone experiences moderate to severe acute pain at some time, most CLINICAL PERSPECTIVE—OPIOID THERAPY OF PAIN • 5 
often in association with surgical procedures, medical 
conditions, or physical trauma. Untreated acute pain 
causes unnecessary suffering, prolongs hospital stays, 
increases medical costs, and may progress to chronic 
pain (Young Casey et al., 2008). Epidemiological stud­
ies indicate that more than 50 million Americans are 
experiencing chronic pain at any given time. Chronic 
pain decreases quality of life and work productivity, and 
the societal costs of untreated chronic pain are high 
(Collins et al., 2005; McCarberg and Billington, 2006). 
The economic burden of untreated pain in the United 
States is estimated to be more than $100 billion per year 
(see http://men.webmd.com/features/price-tag-on-pain). 
The Nexus of Substance Use Problems and Pain 
The lifetime prevalence of alcohol abuse disorders in the 
U.S. general population is estimated at 16 to 24 percent 
(National Institute on Alcohol Abuse and Alcoholism, 
1998), and about 8 percent of Americans aged 12 and 
older report use of an illicit substance within the past 
month (Substance Abuse and Mental Health Services 
Administration [SAMHSA], 2007). Substance use dis­
orders are significantly more common in many medical 
populations and, for example, reach 19 to 26 percent 
among hospitalized patients (e.g., Brems et al., 2002), 
40 to 60 percent among persons sustaining major trauma 
(Heinemann et al., 1988; Norman et al., 2007), and 5 
to 67 percent among persons being treated for depres­
sion (Sullivan et al., 2005). Because the same popula­
tions are at high risk for experiencing acute and chronic 
pain, the prevalence of substance use problems among 
persons treated for pain is high. 
Conversely, pain is common in populations seeking 
treatment for addictive disease. A recent study found 
that 37 percent of patients in methadone maintenance 
treatment programs (MMTPs) and 24 percent of patients 
admitted for treatment of addiction experienced severe 
chronic pain (Rosenblum et al., 2003). In this study, 80 
percent of MMTP patients and 78 percent of inpatients 
reported pain of some type and duration. 
Clinical and Ethical Challenges 
Persons with substance use disorders are less likely than 
others to receive effective pain treatment (Rupp and 
Delaney, 2004). The primary reason is clinicians’ con­
cern that they may misuse opioids. Although mild to 
moderate pain can often be treated effectively with a 
combination of physical modalities (e.g., ice, rest, and 
splints) and nonopioid analgesics (e.g., nonsteroidal 
anti-inflammatory drugs [NSAIDs], acetaminophen, 
or other adjuvant medications), management of severe 
pain, especially when cancer-related, often requires opi­
oids. Moreover, physicians are increasingly using opi­
oids to treat chronic non-cancer-related pain, and an 
emerging body of evidence suggests that, for some patients, 
this approach both reduces pain and may foster modest 
improvements in function and quality of life (Devulder, 
Richarz, and Nataraja, 2005; Haythornthwaite et al., 
1998; Kalso et al., 2004; Martell et al., 2007; Noble et 
al., 2008; Passik et al., 2005; Portenoy et al., 2007; 
Portenoy and Foley, 1986). 
The use of opioids in persons with a history of 
substance use disorders raises not only complex clinical 
issues, but also ethical issues. The principles of benefi­
cence and justice demand that all persons have equal 
access to effective pain treatment; however, the obliga­
tion to provide relief can come into tension with the 
principle of nonmaleficence (primum non nocere, “first, 
do no harm”) when a patient’s substance use problem 
raises concerns about potential medication misuse and 
resulting harmful consequences (Cohen et al., 2002). 
THE EXPERIENCE OF PAIN 
Chronic pain complicates the efforts of many individ­
uals with substance use disorders to enter and sustain 
recovery (Passik et al., 2006a). An understanding of the 
nature and components of pain can help addiction pro­
fessionals to understand the relation of each client’s pain 
to his or her addiction and thereby to provide more effec­
tive assistance on the path to recovery. 
The Multidimensional Nature of Pain 
In the early 1970s, the International Association for the 
Study of Pain (IASP) adopted a definition of pain that 
is still widely accepted. It states that pain is “an unpleas­
ant sensory and emotional experience, associated with 
actual or threatened tissue damage, or described in terms 
of such” (IASP Task Force on Taxonomy, 1994, p. 213). 
This definition honors the understanding that pain is 
subjective, an experience rather than an objectively ver­
ifiable occurrence; it recognizes that pain has both 
sensory and affective dimensions; and it affirms that pain 
can exist in the absence of actual tissue pathology. In 
affirming the subjective, emotional, and sensory nature 
of pain and the fact that it may occur in the absence of 
an identifiable cause, the definition encourages clini­
cians to address all complaints of pain seriously. 
Although some persons may feign pain in order to 
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FIGURE 1. Nociceptive Pain 

In nociceptive pain, sensory nerves function nor­
mally. The place where pain signals originate and 
the place that hurts are the same—in this case, a 
hand that has come into contact with a hot object. 
FIGURE 2. Neuropathic Pain
 
In neuropathic pain, injury to nerves (inset) or 
changes in processing of nerve signals may spon­
taneously generate pain signals, though no fresh 
injury or insult is occurring. Here, changes in nerve 
processing at different points along the pain path­
ways may cause the woman’s hand to hurt even 
after her tissues have otherwise healed. 
obtain opioids for non-pain­ iologically, an individual’s pain derives from a noci­
related purposes, and persons  ceptive, neuropathic, or mixed mechanism. Temporally, 
with co-occurring pain and  the pain is acute if it resolves along with its initiating 
addiction sometimes may have  physical causes, and chronic if it persists. 
difficulty knowing where pain 
ends and a craving for opioids  Physiological Basis of Pain 
begins, most pain complaints  Nociceptive Pain. Nociceptive pain is induced by actual 
are driven by real distress, the  tissue damage. It is evoked by intense stimulation of sen­
components of which usually  sory receptors that alert the body to a potential for phys­
can be defined with careful  ical harm. Usually, the pain occurs at the site of the insult 
evaluation. Dynamic radio­ (Figure 1). The sensation most often reflects the type of 
logical studies such as positron  stimulus (e.g., spasms feel tight; cuts feel sharp; and 
emission tomography (PET)  burns feel hot). Nociceptive pain is often self-limited, 
scans and functional magnetic  resolving spontaneously as the threat passes or the injury 
resonance imaging (fMRI)  heals. It may persist, however, if tissue damage persists 
yield useful objective anatom­ (for example, in chronic degenerative arthritis or advanc­
ical and physiological infor­ ing cancer). Nociceptive pain may be intermittent when 
mation about pain in experi­ the cause is intermittent, for example, in acute recurrent 
mental contexts and hold  pancreatitis or sickle cell anemia. The cause of nocicep­
promise for future clinical  tive pain usually becomes apparent from the patient’s 
use in pain documentation  history, a physical examination, and/or imaging or 
(Mackey and Maeda, 2004).  laboratory studies. 
However, given the complex  Neuropathic Pain. Neuropathic pain results from 
nature of the experience of  aberrant functioning along the neural pathways that 
pain, such technology is  normally conduct nociceptive pain (Figure 2). There are 
unlikely to be a reliable clin­ numerous types of neuropathic pain. Among the more 
ical tool to distinguish actual  common: 
from feigned or mislabeled  • Tissue may compress a nerve, as in a lumbar disc rup­
pain in the near future, if ever.  ture or carpal tunnel syndrome, which causes pain 
The spectrum of chronic  in the area served by the nerve. 
pain disorders experienced by  • Peripheral nerve fibers that have been injured by lac-
persons with addictive disor­ eration or prolonged compression may regenerate in 
ders is similar to that of the  a disorganized manner, producing either neuritis (result­
general population. Common  ing in abnormal signal conduction) or a neuroma 
syndromes include headache,  (clumped aggregation of neural fibers) that perpetu­
low-back and neck pain, myal­ ates pain with minimal or no stimulus. (For another 
gias and arthralgias, dental  example, see Figure 3.) 
pain, neuropathies, and abdom­ • Impaired blood supply associated with peripheral vas­
inal/pelvic pain. Regardless of  cular disease or hyperglycemia associated with dia­
its anatomical focus, all pain  betes may impair small nerve fiber function in the 
draws from a shared pool of  hands or feet, causing bilateral symmetrical pain (periph­
etiological mechanisms and  eral neuropathy). 
shares general principles of  Neuropathic pain also can result from disruption of 
evaluation and management.  the normal relationship between peripheral neurons and 
the secondary neurons in the spinal cord that relay sen-
The Classification of Pain  sory signals to the brain and other sites. Thus, untreated 
Pain can be classified in terms  severe nociceptive pain may cause a continuing barrage 
of its physiological mecha­ of stimuli to secondary neurons, resulting in hyper-reac­
nisms and its duration. Phys­ tivity or central sensitization of the nerves, which may CLINICAL PERSPECTIVE—OPIOID THERAPY OF PAIN • 7 
then translate nonpainful signals into pain, sometimes  pathic pain may be superim­
termed “wind-up phenomena” (Curatolo et al., 2006).  posed on a focal pain syndrome, 
Conversely, loss of neural input into the spinal cord—  for example, when a severely 
for example, following loss of a limb—may result in  painful nondisplaced bone 
amplification of signals coming from the periphery and  fracture is undetected, no pain 
lead to deafferentation or “phantom” pain.  treatment is provided, and sec-
Still other types of neuropathic pain have central or  ondary sensitization develops, 
regional origins. Injury to certain parts of the central  presenting as a generalized pain 
nervous system—such as the thalamus, a prominent  syndrome in which “every­
pain-processing center in the brain, due to a stroke (Jensen  thing hurts.” 
and Lenz, 1995) or the dorsal horn, a pain-processing 
center of the spinal cord, due to herpes zoster or shin- Acute and Chronic Pain 
gles—may cause pain in body areas whose neural sig- Acute pain has an abrupt onset 
nals travel through the injured area (Figure 4). Aberrant  and can be severe (see www. 
central neural processing of nonpain signals due to abnor­ cancer.gov/cancertopics/pain 
mal neurotransmitter activity is now thought likely to  control/page2 ). It is usually asso­
be responsible for fibromyalgia syndrome, which pres­ ciated with an acute physical 
ents with diffuse, generalized, or multifocal pain (Mease,  condition, and its etiology is 
2005). Persistent arousal of a localized region of the sym­ usually—though not always— 
pathetic nervous system may contribute to a complex  known or identifiable. The pain 
regional pain syndrome, a neuropathic pain of complex  is self-limited and generally 
etiology (Burton, Bruehl, and Harden, 2005).  resolves as the underlying injury 
Neuropathic pain has variable presentations, but  or disease process resolves. Acute 
most often is described as burning, shooting, aching,  pain is often primarily noci­
tingling, electrical, or “pins and needles,” often with an  ceptive, but may have a neu­
associated sense of numbness. Objective physical find­ ropathic component if nerves 
ings in neuropathic pain are sometimes subtle or non- are affected by a lesion or 
existent, making the patient’s history and pain descrip­ process. Severe acute pain fre­
tion especially important to the diagnosis. This may lead  quently is associated with sym­
to skepticism on the part of care providers that becomes  pathetic responses reflected in 
the basis for a mistrustful therapeutic relationship, par- signs such as increased blood 
ticularly when the patient has a history of substance use  pressure and pulse, sweating, 
and opioids may be indicated for treatment.  blanching of the skin, and 
Mixed Pain Mechanisms. Many common pain syn­ hyperventilation. An individ­
dromes combine nociceptive and neuropathic pain. Back  ual in acute pain often appears 
pain due to severe degenerative arthritis may be associ­ distressed. 
ated with referred leg pain caused by degenerative changes  Chronic pain differs from 
that are compressing or injuring a lumbar nerve root.  acute pain in that it no longer 
Neck pain following a cervical strain may be due to spinal  serves survival or any other 
facet joint irritation and to cervical muscle spasm, which  beneficial purpose and has lin­
in turn may cause brachial plexus irritation and referred  gered past the limits normally 
arm pain. A person with a peripheral neuritis due to  associated with tissue healing 
nerve injury in the leg may have an abnormal gait that  (Mersky and Bogduk, 2004). 
leads to mechanical back pain. A cancer tumor may cause  It may persist because of chronic 
pain due to both local tissue invasion and neural com­ ongoing tissue pathology (e.g., 
pression. Headaches have many different etiologies, but  degenerative arthritis, persist-
some are due to cervical muscular tension with irrita­ ent muscle spasm, chronic pan­
tion of the greater occipital nerves that radiates pain to  creatitis, or progressive can-
the back of the head and temples. Generalized neuro­ cer), an established neuropathic 
FIGURE 3. Displaced Sensation of 
Neuropathic Pain 
In some types of neuropathic pain, the source of 
the pain and the sensation of hurt occur in differ­
ent locations. In this example, one of the spongy 
discs that alternate with the spinal vertebrae has 
ruptured, leaking material that presses on an adja­
cent large nerve fiber (inset). Pain signals travel 
from the pinched fiber to the brain, which inter­
prets them as coming from the peripheral tissues 
served by the fiber. 
FIGURE 4. Neuropathic Pain With 
Damaged Pain-Processing Areas of 
the Brain 
Damage to pain-processing areas in the brain also 
can result in neuropathic pain that is “referred”— 
that is, felt elsewhere. In this example, an injury to 
the thalamus (inset) causes pain in a shoulder. 8 • ADDICTION SCIENCE & CLINICAL PRACTICE—JUNE 2008 
pain mechanism, or a combination of the two. 
Pain that persists for a prolonged period of time often 
engenders secondary problems, such as sleep disturbance; 
anxiety; depressive symptoms; loss of normal function 
in work, social situations, and recreation; and increased 
stress associated with these losses. In turn, fatigue, mood 
disturbance, and stress may expand the experience of 
pain; such cycles often sustain the experience of chronic 
pain even when the physiological basis improves. Some­
times, the underlying physiological basis of chronic pain 
is difficult to determine with precision, because it is 
wrapped in many layers of associated problems and dis­
tress. Effective treatment of chronic pain often must 
address the context in which the pain occurs, the mul­
tidimensional impact of the pain, and the feedback cycles 
that may serve to sustain it. 
Chronic pain is not usually associated with sympa­
thetic arousal. Therefore, objective signs of physiolog­
ical stress are often absent, and persons with chronic pain 
may not appear to be hurting. In such cases, observers 
are sometimes skeptical, particularly when substance 
problems or opioid medications are involved. However, 
persons with chronic pain also may experience periods 
of acute exacerbation that are associated with sympa­
thetic responses and more obvious physical distress. 
The Synergy of Pain and Addiction 
Addiction may affect the experience of pain in a num­
ber of ways. Although an addicted individual may per-
FIGURE 5. Synergy of Pain and Addiction 
ceive that alcohol or drug use helps him or her cope with 
ongoing pain, the reality is generally otherwise. When 
chronic pain and addiction co-occur, each may reinforce 
components of the other (Figure 5). 
Like chronic pain, addiction often results in non-
restorative sleep, anxiety and/or depression, inability to 
function in important life roles, and resultant stress. 
In addition, persons who are addicted to a substance 
rarely use it in a manner that creates a steady state and 
physiological homeostasis. Rather, they tend to expe­
rience periods of intoxication, followed by periods of 
withdrawal. The alternation of periods of relative auto­
nomic and psychomotor inactivity during intoxication 
with periods of physiological stress, sympathetic arousal, 
and muscular tension during withdrawal has been char­
acterized as “on–off” or rebound phenomenon, and may 
increase pain (Dunbar and Katz, 1996; Pud et al., 2006; 
Savage, 1993). Also, addicted individuals may have dif­
ficulty complying with pain treatment recommenda­
tions because of intoxication and time spent pursuing 
drugs. Clearly, treatment of an active addiction is criti­
cal to the effective management of chronic pain. The 
individual with both pain and addiction, however, may 
perceive his or her drug use as transiently reducing pain 
or improving coping; thus, it is important for addiction 
professionals to provide education on the synergy of pain 
and addiction. 
In the acute pain setting, the pain treatment plan 
must accommodate physical dependence on alcohol, 
opioids, or other drugs, because initiating withdrawal 
may increase pain and interfere with compliance and 
efficacy. At the same time, acute pain associated with 
trauma, surgery, and illness may present an opportunity 
for intervention in substance abuse or addiction, because 
patients are confronted with possible withdrawal and 
their overall vulnerability related to substance use. 
The Uniqueness of Each Pain Experience 
Whatever the physiological basis of pain, the experience 
is filtered through the individual’s biopsychosocial con­
text. The same pain generator may therefore be experi­
enced very differently by different individuals, depend­
ing on their biogenetic makeup, sociocultural expectations, 
gender, co-occurring medical and psychiatric conditions, 
and other factors (Kim et al., 2004). 
PRINCIPLES OF PAIN ASSESSMENT 
Addiction professionals may need to evaluate pain and 
consider pain management approaches for their patients CLINICAL PERSPECTIVE—OPIOID THERAPY OF PAIN • 9 
in a number of situations. Some patients in addiction 
treatment struggle to enter recovery because of persist­
ent pain that interferes with substance cessation; some 
patients in recovery develop pain that threatens sobri­
ety; and some patients have difficulty discerning whether 
prescribed opioids continue to be necessary for their 
underlying pain or whether their continued need is 
related to craving that is masquerading as pain. Although 
addiction clinicians will not employ all elements of pain 
assessment and treatment, they will be better able to sup­
port effective pain management if they possess a broad 
understanding of the relevant principles. 
In acute settings, where pain is consistent with an 
identified or suspected cause and is likely to be self-lim­
ited, the only critical assessment is often pain inten­
sity, which provides a basis for evaluating the effective­
ness of interventions. Clinicians usually ask patients 
to rate their pain intensity with a numerical rating scale 
of 0 to 10 or a visual analog scale. Sometimes verbal 
descriptor scales and facial distress image scales may be 
useful, particularly in children or persons with cogni­
tive challenges. 
When pain is persistent, clinicians must assess not 
only the pain itself, but its overall impact on the indi­
vidual, including associated psychosocial factors. The 
workup should include a detailed assessment of the pain, 
including its intensity, quality, location, and radiation; 
identification of factors that increase and decrease the 
pain; and a review of the effectiveness of any interven­
tions that have been tried to relieve the pain. The inten­
sity of chronic pain often fluctuates, and knowledge of 
the pattern may help guide treatment; therefore, it may 
be helpful to inquire not only about current pain, but 
also about the worst, least, and typical pain experienced 
over the past week. In addition, it is important to ask 
the patient what level of pain permits a good quality of 
life, as different individuals find widely varying levels of 
pain acceptable or debilitating. 
The impact of chronic pain on sleep; mood; level of 
stress; and function in work, relationships, and recre­
ational activities should be assessed, because improve­
ment in these domains may be a goal of pain treat­
ment and a measure of the efficacy of interventions. 
Numerous screening instruments are available to assist 
in these assessments, including, among many others, the 
Brief Pain Inventory; the Roland Morris Disability Scale; 
and the nine-item Patient Health Questionnaire, which 
is a brief measure to identify depression, the most com­
mon psychiatric problem seen among pain patients. 
Assessment of co-occurring medical and psychiatric con­
ditions is important in order to appreciate variables that 
may impede pain recovery. A physical examination and 
imaging and laboratory studies may be helpful diag­
nostically, but these are not generally included in a non­
medical addiction professional’s assessment. 
Assessment of medication and other drug use is crit­
ical to understanding and addressing pain, particularly 
in persons at risk for or with a history of substance use 
disorders. Useful information includes: 
• What substances, including alcohol, illicit drugs, or 
prescription drugs, is the individual currently using? 
At what dosages? How often? 
• What substances does the individual believe ease, or 
help him or her cope with, the pain? 
• How does each substance affect the pain? 
• Do the substances have effects other than analgesia 
that the individual identifies as beneficial, such as 
reward/euphoria, sedation, relief of anxiety or depres­
sion, or sleep induction? 
• What unwanted effects or side effects does each sub­
stance have? 
• Does the individual experience withdrawal symptoms 
if he or she does not use the substance? 
• How is each substance obtained (e.g., prescribed, over 
the counter, borrowed, or bought on the street)? 
• Is the individual using any nonprescribed medications 
or street drugs that he or she does not relate to pain 
management? 
PRINCIPLES OF PAIN TREATMENT 
The armamentarium of pain treatment tools is vast and 
varied. The most appropriate interventions will depend 
on a number of variables, including the location and 
nature of the patient’s pain and its psychosocial context, 
the availability of specific interventions, the patient’s 
preferences, the treatment provider’s clinical orienta­
tion, and the relative risks and benefits of particular inter­
ventions vis-à-vis the patient’s other co-occurring con­
ditions, including previous or ongoing substance use. 
Whenever possible, it is important to identify and address 
the underlying pain generator; this is the key to reduc­
ing all acute pain and many cases of chronic pain as well, 
although “fixing” the problem is not always possible in 
chronic pain. 
Tools for managing pain fall into four broad cate­
gories: physical interventions, psychobehavioral approaches, 
interventionist treatments (invasive procedures), and 
medications (Table 1). Often a combination of approaches 
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TABLE 1. Common Pain Treatments 
PHYSICAL 	 PSYCHOBEHAVIORAL  INTERVENTIONIST  MEDICATION CLASSES 
Thermal: heat and ice 
Counterstimulation: transcu­
taneous electrical nerve stim­
ulation (TENS), vibration 
Exercise: stretching, strength­
ening, conditioning 
Manual therapies: massage, 
manipulation 
Orthotics, braces, pillows, 
splints 
Acupuncture 
Relaxation, biofeedback	  Nerve blocks and ganglion  Nonsteroidal anti-inflam­
injections  matory drugs (NSAIDs),
Stress reduction, psychother­ acetaminophen
apy for co-occurring psycho- Steroid joint injections 
logical stress issues  Anticonvulsants 
Trigger point injections 
Cognitive restructuring  Antidepressants with
Epidural steroids  noradrenergic effects
Pacing, behavioral modifica-
Spinal cord stimulation	  (e.g., tricyclics, duloxetine,
tion  venlafaxine)
Spinal infusions Treatment of mood distur­
bance 
Sleep management 
is most effective. Combining interventions that act at 
different points along the pathways of pain—for exam­
ple, in the peripheral tissues, the nerves, the spinal cord, 
or the brain—may yield complementary additive or syn­
ergistic effects. 
In general, addiction clinicians do not bear primary 
responsibility for directing pain treatment, but a famil­
iarity with pain management options will enable them 
to advocate for appropriate treatment and to help patients 
identify and apply self-management strategies for pain. 
A knowledgeable and supportive advocate may be a 
patient’s most important asset in receiving effective care. 
In many cases, unfortunately, the greatest challenges lie 
in identifying skilled clinicians willing to work with 
patients with co-occurring pain and addiction and in 
finding financial support for treatment. 
Treating Acute Pain 
Mild to moderate acute pain is often relieved by physi­
cal interventions—such as the application of ice, tran­
scutaneous electrical nerve stimulation (TENS), mas­
sage or stretching, and/or bracing—along with a mild 
analgesic such as an NSAID or acetaminophen. More 
severe pain often requires opioid therapy, which will be 
discussed in depth below. When appropriately skilled 
clinicians are available in a system that is comfortable 
supporting such treatments, nerve blocks or spinal infu­
sions can sometimes control more severe acute pain. 
Examples of common acute pain procedures are rib 
blocks for rib fractures or thoracic incisions; epidural 
infusions for thoracic, abdominal, or lower body sur­
gery or trauma; and brachial plexus infusions for upper 
Topicals: lidocaine, 
capsaicin, aromatics 
Opioids 
Miscellaneous 
extremity postsurgical or trauma-related pain. 
Clinicians should generally not let concerns about 
addiction deter them from using opioids that are needed 
for severe acute pain. Carefully supervised short-term 
use of opioids in the context of time-limited treatment 
of such pain has not been documented to affect the long-
term course of addictive disorders. Rather, inadequate 
pain control and treatment that frustrates, stresses, or 
confuses patients may lead to relapse (Wasan et al., 2006). 
Managing Chronic Pain 
Although opioid therapy is sometimes a component 
of chronic pain management, nonopioid interven­
tions control many cases of mild to moderately severe 
chronic pain. A specific treatment can sometimes sig­
nificantly reduce or resolve chronic pain, but successful 
treatment is frequently a multidimensional process that 
demands the patient’s active engagement. Addiction 
treatment clinicians, as they work to induce and sup­
port recovery, are in an excellent position to help patients 
implement components of the pain management process. 
Common components include: 
• Raising the patient’s awareness of factors that increase 
and relieve the pain, and accommodating behaviors 
to reduce pain (e.g., cognitive-behavioral approaches); 
• Improving physical fitness, including flexibility, strength, 
and conditioning, while respecting any limits imposed 
by the pain; 
• Reducing stress and the associated muscular/auto­
nomic tension; 
• Selectively using specific therapeutic interventions 
such as injections, therapeutic exercise, and orthotics; CLINICAL PERSPECTIVE—OPIOID THERAPY OF PAIN • 11 
• Making strategic use of self-administered care inter­
ventions, such as the application of ice or heat, TENS, 
stretching, relaxation, and splints; and 
• Using nonopioid analgesic medications, such as acet­
aminophen, NSAIDs, tricyclic antidepressants, 
anticonvulsants, and topically applied agents, singly 
or in combinations that take advantage of comple­
mentary mechanisms of action. 
The goals of chronic pain treatment most often 
include, along with reduction of pain, relief of associ­
ated symptoms such as anxiety, depression, or sleep dis­
turbance and increased function in valued social, 
vocational/avocational, creative, and recreational roles. 
Helping the patient to identify alternative avenues to 
satisfaction in these domains is sometimes necessary 
when pain or disability prevents participation in prior 
roles. 
OPIOID CONSIDERATIONS IN PAIN 
TREATMENT 
Despite important advances in pain treatment, opioids 
remain the most potent class of analgesic medications 
available. They relieve most types of pain, are widely 
available, and are generally safe when used appropriately. 
Unlike some other analgesics, opioids do not cause organ 
toxicity when used appropriately; in contrast, NSAIDs 
and acetaminophen can cause serious gastric, hepatic, 
and renal toxicities, which are responsible for 15.3 deaths 
per 100,000 users per year (Lanas et al., 2005; Nourjah 
et al., 2006). However, opioids may be misused by indi­
viduals to obtain an opioid high or to self-medicate mood 
disturbances, and in vulnerable individuals, use of 
opioids may lead to addiction. When misused, opioids 
can cause death through respiratory suppression lead­
ing to cardiac arrest. There is growing evidence that in 
some individuals, long-term opioid use may alter pain 
processing in a way that actually increases pain (Angst 
and Clark, 2006; Baron and McDonald, 2006; Chang, 
Chen, and Mao, 2007). Finding a balance between 
the benefits and risks of opioid use is often challenging 
and requires a fundamental understanding of opioid 
actions and conditions related to their use. 
Prevalence of Opioid Misuse 
The therapeutic use of opioids has increased significantly 
in recent years. The U.S. Drug Enforcement Adminis­
tration, which monitors the distribution of opioids 
through legitimate channels from manufacturer to phar­
macy, recorded more than a quadrupling in annual quan­
tities of oxycodone products and methadone distributed 
for therapeutic use between 1997 and 2002. Distribu­
tion of most other opioids increased as well, though less 
markedly. In a similar timeframe, between 1996 and 
2001, emergency room visits related to misuse of pre­
scription opioids more than doubled (Drug Abuse Warn­
ing Network, 2002). In 2003, the National Survey on 
Drug Use and Health found that 4.9 percent of adults 
and 7.7 percent of children between the ages of 12 and 
17 acknowledged nonmedical use of a prescription opi­
oid in the past month (SAMHSA, 2005). The num­
ber of people admitted to federally funded treatment 
centers with a primary diagnosis of prescription opi­
oid addiction more than tripled, from 0.9 to 3.5 per­
cent, between 1992 and 2004 (SAMHSA, 2005). 
Diversion of prescription opioids from legitimate 
therapeutic channels is clearly occurring, but it is uncer­
tain which points in the distribution system are leaking 
the most. Diversion at the level of patient prescriptions 
likely contributes substantially to illicitly available med­
ications, but it appears that truck and pharmacy rob­
beries also contribute (Joranson and Gilson, 2005). Indi­
viduals with substance use disorders appear to be at 
greatest risk for misuse of prescription opioids, but other 
variables carry a risk as well, including youth, smoking, 
a family history of addiction, and comorbid psychiatric 
problems associated with impulsivity (Kahan et al., 2006; 
Webster and Webster, 2005). 
Opioid Analgesic Considerations 
Opioids provide pain relief (analgesia) through action 
at mu, kappa, and/or delta receptors distributed through­
out the central nervous system, including both the brain 
and spinal cord, and, to a lesser degree, the peripheral 
nervous system (Amabile and Bowman, 2006). Clini­
cally available opioid medications act predominantly at 
mu or kappa receptors. Opioid receptor activation at 
different sites contributes to analgesia through several 
mechanisms, including direct inhibition of pain trans­
mission at the dorsal horn of the spinal cord, activation 
of brain centers that transmit pain-inhibiting signals 
downward through pathways (serotonergic and nora­
drenergic) in the spinal cord, inhibition of pain recep­
tors in the peripheral tissues, and stimulation of lim­
bic activity that alters perceptual and affective responses 
to pain (Inturrisi, 2002). 
Mu Opioids 
The most commonly used opioid analgesics act at mu 
Long-term 
opioid use may 
alter pain-
processing 
in a way that 
actually 
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TABLE 2. Mu Agonist Opioids and Kappa Opioids 

OPIOID 
Mu Agonist Opioids 
Morphine 
Oxycodone 
Hydrocodone 
Hydromorphone 
Fentanyl 
Methadone 
Tramadol 
Buprenorphine 
Codeine 
Kappa Opioids 
Butorphanol 
Nalbuphine 
Pentazocine 
EXAMPLE BRANDS/ 
PREPARATIONS 
MS Contin (12-hour CR), Kadian, 
Avinza (24-hour CR), Oramorph 
(IR) 
Percocet (IR and acetamino­
phen), Percodan (IR and aspirin), 
OxyContin (12-hour CR) 
Vicodin (IR and acetaminophen), 
Lortab (IR and acetaminophen) 
Dilaudid (IR) 
Duragesic (72-hour CR patch), 
Actiq (IR lozenge) 
Methadose, Dolophine 
Ultram (IR), Ultracet (IR with 
acetaminophen) 
Subutex (used for pain, but not 
FDA approved for pain) 
Tylenol #3 (IR with acetamino­
phen) 
Stadol (IV or intranasal) 
Nubain (IV only) 
Talwin, Talwin NX (with naltrex­
one) (oral only) 
SPECIAL PAIN ISSUES 
CR mechanism provides rela­
tively stable blood levels 
CR mechanism provides rela­
tively stable blood levels 
The most commonly prescribed 
opioid (Hughes, Bogdan, and 
Dart, 2007) 
Patch provides very stable blood 
levels when used as prescribed 
Mu opioid; in addiction, pro­
motes analgesia by a second 
mechanism: NMDA receptor 
antagonism; produces tolerance 
less readily than other mu 
opioids 
Promotes analgesia by a second 
mechanism: increasing sero­
tonin/norepinephrine; doses 
are limited due to risk of 
seizures 
Partial agonist; ceiling effect; 
used off label for pain 
Metabolism to morphine is a 
rate-limiting step that creates a 
ceiling of analgesia in most 
people 
Rapid onset of intranasal; ceil­
ing analgesic effects 
Ceiling analgesic effects 
Ceiling analgesic effects 
SPECIAL MISUSE ISSUES 
CR mechanism may be altered for misuse 
CR mechanism may be altered for misuse 
Most commonly misused opioid 
Quick onset; relatively high reward value 
Misuse of patch can be particularly dan­
gerous due to concentrated 3-day supply 
of opioid 
Misuse and mortality related to misuse 
have recently increased; pharmacological 
properties make misuse particularly risky 
Relatively low rates of abuse and reward 
documented in some persons 
Approved for treatment of opioid addic­
tion; some IV abuse reported 
Some patients experience less reward than 
with mu opioids, but intranasal route is 
quick onset 
Some patients experience less reward than 
with mu opioids 
Some patients experience less reward than 
with mu opioids; formulated with naltrex­
one due to IV abuse in 1960s 
Abbreviations: CR, controlled release; FDA, Food and Drug Administration; IR, immediate release; IV, intravenous; NMDA, N-methyl-D-aspartic 
acid. 
opioid receptors (Table 2; Figure 6). Most of these mu  madol (Ultram), which is dose-limited because it low-
opioids can be titrated as needed to achieve relief of acute  ers the seizure threshold; meperidine (Demerol), whose 
pain and have no ceiling of analgesia. Exceptions are tra- metabolite, normeperidine, may be neurotoxic at high CLINICAL PERSPECTIVE—OPIOID THERAPY OF PAIN • 13 
doses; codeine, which relies on metabolism to morphine 
for much of its analgesia but is not metabolized fast 
enough for unlimited pain control; and buprenorphine, 
which is a partial mu agonist that has an intrinsic ceil­
ing effect. Recent evidence suggests that methadone at 
higher doses may contribute to cardiac arrhythmia in 
some patients; hence, titration to higher levels may require 
special cardiac monitoring (Peles et al., 2007). Opioids 
can relieve both somatic and neuropathic pain; however, 
there appears to be a shift in the dose–response curve in 
neuropathic pain syndromes, such that a higher dose of 
the opioid is required to achieve analgesia. 
Individuals vary in their analgesic responses and the 
side effects they experience with different mu opioids. 
The main reason appears to be that each mu opioid acts 
more strongly at certain mu subreceptors and more 
weakly at others, and people differ genetically in the pro­
portions of the various subreceptors present in their sys­
tems (Mercadante, 1999; Pasternak, 2005; Thomsen, 
Becker, and Eriksen, 1999). 
Kappa Opioids 
Kappa opioid analgesics, though not widely used, pro­
vide analgesia through kappa opioid receptors (Table 2). 
Kappa opioids are usually antagonists at the mu recep­
tors; they cannot be used in combination with mu 
opioids, as they reverse mu opioid analgesia and may 
cause withdrawal in physically dependent persons. Kappa 
opioid analgesics have a ceiling of analgesic effect and 
are appropriate for use in moderate, but not severe, pain. 
Opioid Side Effects 
Side effects of mu opioids are dose-related and include 
sedation, cognitive blurring, respiratory depression, 
meiosis (pupillary constriction), nausea, urinary reten­
tion, constipation, and reward. Except for constipation, 
side effects tend to be transient and generally resolve 
within a few days at a stable dosage. Side effects may 
reemerge with an increase in dosage. 
Compared with mu opioids, kappa agonists have a 
lower incidence of side effects such as sedation, respira­
tory depression, and nausea. Reward appears less com­
mon as well, although some individuals do misuse these 
medications for euphoria. Dysphoria is a relatively com­
mon side effect of kappa agonists. 
Effective treatments are available for most opioid 
side effects when they persist. Many studies have docu­
mented that cognitive and sedative side effects of opi­
oids are negligible in most persons using a stable dose 
FIGURE 6. Opioids’ Analgesic Activity
 
Brain centers of opioid 
pain control: 
Periaqueductal gray 
Nucleus raphe magnus 
Rostral ventral medulla 
Mu opioids block pain mainly by activating mu opioid receptors. 
An important site of opioid pain suppression is the dorsal horn 
(inset). Here, mu opioids (shown in gold) attach to receptors 
(dark blue), inhibiting peripheral fibers from transmitting incom­
ing pain signals (blue arrow), and spinal neurons from receiving 
them. Simultaneously, signals (purple arrow) triggered by mu 
opioid activation in the brain further inhibit the responsiveness 
of spinal neurons. As a result of these actions, pain signals 
relayed up the spine (white arrow) are weakened or abolished. 
over a prolonged period of time. Therefore, most per­
sons who use opioids on a long-term basis for analge­
sia may perform high-level mental and physical work 
without compromise of function (e.g., Gaertner et al., 
2006; Zacny, 1996). 
The possibility of opioid-induced hyperalgesia (increas­
ing pain or pain sensitivity) must be considered when 
pain continues to worsen without any other identifiable 
cause in a patient using high doses. One possible cause 
of this phenomenon is that opioids may activate N­
methyl-D-aspartic acid (NMDA) receptors, which has 
been shown to cause neuropathic pain experimentally. 
The relationship between opioid tolerance and opi­
oid-induced hyperalgesia is a subject of intense inter­
est among opioid researchers and pain clinicians (Chang, 
Chen, and Mao, 2007). 
Patients must sometimes be tapered off opioids when 
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ing side effects, pain, or other concerns, and switching 
to another opioid does not help. Sometimes patients 
improve clinically with lower doses or cessation of opi­
oids (Baron and McDonald, 2006). If pain increases 
during a taper from opioids, alternative approaches to 
pain management should be intensified. 
Tolerance to Opioids 
Tolerance is a state of adaptation in which exposure to 
a drug induces changes that result in diminution of one 
or more of its effects over time (American Society of 
Addiction Medicine [ASAM], 2001). Individuals com­
monly become tolerant to the analgesic effects and side 
effects of opioids; this should not be considered an indi­
cator of addiction in the context of the pain treat­
ment. Most often, tolerance to side effects such as res­
piratory depression, nausea, and sedation develops more 
Tolerance and  rapidly than tolerance to analgesia, permitting doses 
to be escalated as necessary with appropriate monitor- dependence 
ing to achieve effective pain control. Constipation, how-
are not 
ever, may be a persistent problem requiring specific treat-
indicators of  ment. 
addiction in  Tolerance to the opioid analgesia may be addressed 
the context  in several ways. Often, the physician simply increases 
the dosage. However, if a patient appears to develop rapid  of pain 
or persistent tolerance to a particular opioid, or if per-
treatment. 
sistent side effects occur at higher doses, switching to an 
alternative opioid may sustain or improve analgesia while 
alleviating the problematic effect. A caveat with this strat­
egy is that rotation from methadone to other opioids 
does not routinely improve analgesia. It has been hypoth­
esized that methadone is a “broader spectrum” opioid 
(i.e., activates a more complete spectrum of mu subre­
ceptors; Pasternak, 2005) or that methadone maximally 
activates the opioid receptors to which it binds, such 
that there is a loss of relative opioid effect with substi­
tution of other mu opioids, which decrease relatively the 
number of receptors activated (Kreek, 1973). 
Opioid Physical Dependence 
Physical dependence is a state of physiological adapta­
tion that manifests in a drug-class-specific withdrawal 
syndrome that could result from abrupt cessation, rapid 
dose reduction, a fall in blood level, or administration 
of an antagonist (ASAM, 2001). Many medications pro­
duce physical dependence, including those that have 
potential reward effects, such as opioids or benzodi­
azepines, and some that do not, such as prednisone, tri­
cyclic antidepressants, and many antihypertensive med­
ications. Physical dependence on opioids, like tolerance, 
is common after continuous use for pain and, in this 
context, does not indicate addiction. Physical depend­
ence and tolerance may or may not be present with mis­
use of or addiction to opioids; they do not, in and of 
themselves, indicate misuse or addiction. 
Reward Considerations 
The potential for patients receiving opioids for pain 
treatment to experience reward is a critical factor to con­
sider when assisting patients with co-occurring pain and 
substance use disorders. A clear understanding of the 
potential issues that drive opioid reward will allow addic­
tion professionals to better understand their patients’ 
subjective experiences of these medications and to think 
through options for reducing negative impact. 
Mechanisms of Reward 
Opioids produce reward by binding to GABAergic 
interneurons that normally inhibit dopamine produc­
tion in the limbic reward system and preventing them 
from doing so (Hurd, 2006). The resulting increase in 
dopamine and the cascade of secondary effects produce 
feelings of reward. These feelings may occur along with 
analgesia when opioids are used for pain and are not in 
themselves harmful. In some contexts, particularly 
terminal illness, they may, in fact, be a valued side effect. 
However, when euphoria becomes the focus of the use 
of opioids, especially in a person with addictive disease, 
it may undermine pain treatment and become a prob­
lem in its own right. Understanding how to limit opi­
oid reward effects therefore may be helpful. 
Most of what is known about the mechanisms that 
determine reward intensity derives from addiction lit­
erature; this information may, however, also apply and 
provide some guidance in clinical pain treatment set­
tings. Relevant considerations include the rate of increase 
in brain levels of a drug, blood levels of the drug relative 
to individual tolerance, fluctuations in drug blood lev­
els, and the specific receptor profile of the drug with 
respect to individual receptor variability. 
Rate of Increase. Both animal drug self-administra­
tion studies and human drug-liking studies have demon­
strated that reward increases with the rate of rise in drug 
blood levels; the faster the influx of drug into the blood, 
the better the rush or high (Marsch et al., 2001). A recent 
study to determine which properties of prescription opi­
oids make them more attractive for purposes of get­
ting high supported the speed of onset as a key value CLINICAL PERSPECTIVE—OPIOID THERAPY OF PAIN • 15 
(Butler et al., 2006). 
In the setting of therapeutic opioids, the intravenous 
route of administration causes a more rapid rise in blood 
levels and is expected to provide more euphoria than the 
oral route. Intramuscular and subcutaneous adminis­
tration provides an intermediate effect. Among opioids 
given orally, those with an inherently slower time to peak 
effect (such as methadone or levorphanol [Levo-Dro­
moran]) are expected to produce weaker reward effects 
than opioids with relatively rapid onset, such as imme­
diate-release oxycodone (in Percocet or Percodan), 
hydrocodone (in Vicodin or Lortab), or hydromorphone 
(Dilaudid). 
Peak Blood Level Attained. The higher the opioid 
blood level relative to the individual’s tolerance for the 
drug, the greater the reward. An opioid-naive individ­
ual with little or no tolerance may experience euphoria 
with a drug blood level that would cause no signifi­
cant reward effect in a more tolerant individual. A dose 
of an opioid given intravenously achieves a higher peak 
in blood level than the same dose administered by the 
oral route; the effect with subcutaneous and intramus­
cular administration is, again, intermediate (Figure 7). 
As the rise in the blood level of a drug is associated with 
onset of euphoria, stable levels generally produce less 
euphoria than intermittently rising and falling levels. 
This key principle underlies the effectiveness of methadone 
maintenance therapy for opioid addiction. It also fol­
lows that continuous intravenous infusion of an opioid 
will likely trigger less reward than intermittent boluses, 
and controlled-release opioids (used by the intended 
route at the intended time interval) or intrinsically long-
acting opioids (such as methadone or levorphanol) should 
be less rewarding than frequently dosed short-acting 
medications. 
An exception to this rule is patient-controlled 
analgesia (PCA), which is not expected to provide sig­
nificant reward because the incremental doses are very 
small and spaced at intervals that do not permit a rapid, 
high rise in the blood level of the drug (Figure 8). How­
ever, when persons with an active addiction to opioids 
receive PCA or any intravenous infusion, close super­
vision is critical to ensure that there is no tampering with 
the system. 
Receptor Effects. As previously discussed, mu opioids 
are more likely to cause reward than kappa opioids. 
Emerging knowledge of mu opioid subreceptors indi­
cates that individuals may experience varying reward 
effects as well as unequal analgesic effects from a given 
FIGURE 7. Routes of Opioid Administration
 
The appropriate route of opioid administration depends on the clinical goal. The 
intravenous route yields the swiftest but briefest pain control, compared with oral 
and intramuscular/subcutaneous administration, and has the most central nerv­
ous system (CNS) side effects. Oral administration maximizes the duration of 
analgesia and minimizes CNS side effects, but has the longest time to onset of 
relief. 
FIGURE 8. Schedule of Opioid Administration 
Both controlled-release opioids and patient-controlled opioid analgesia (PCA) can 
avoid the central nervous system (CNS) side effects and periods of breakthrough 
pain that may occur during cycles of intermittent short-acting opioid administra­
tion. PCA provides the steadiest level of pain control. 
opioid. Theoretically, this would correlate with the clin­
ical fact that patients treated for opioid addiction iden­
tify different opioids of choice. 
Interference of Pain With Reward 
Some research suggests that people feel less euphoria if 
they are in pain when given opioids and that, therefore, 16 • ADDICTION SCIENCE & CLINICAL PRACTICE—JUNE 2008 
clinicians need not be as concerned about reward in the 
context of pain treatment (Zacny et al., 1996). This 
hypothesis is supported by reports from many patients 
who say that opioids relieve their pain without any psy­
chic effects. Further, many patients experience dyspho­
ria or other aversive feelings, rather than euphoria, when 
given opioids for their pain. 
Modulation of Reward Through Drug Selection and 
Dosing 
Many experts recommend that patients who require opi­
oid therapy to manage around-the-clock pain be placed 
on long-acting medications. The experts believe that, in 
these circumstances, long-acting opioids provide more 
consistent pain relief, more convenience, reduced clock 
watching for pain relief, and the-
TABLE 3. Differential Diagnosis of  oretically, less reward. In addi-
Misuse of Analgesic Opioids 
tion, there is concern that fluc­
tuating blood levels associated  o Misunderstanding of instructions 
with short-acting opioids may  o Elective use for reward or euphoria 
o Compulsive use due to addiction  produce intermittent physio­
o Self-medication of:  logical withdrawal in patients 
• Mood/stress  who become physically depend­
• Sleep  ent—as most do who use these 
• Disturbing memories  medications continuously. With­
• Undertreated pain  drawal could actually increase 
• Other  pain through arousal of the sym­
o Diversion for profit  pathetic nervous system and 
increasing muscular tension. 
Despite these theoretical advantages of long-acting 
or sustained-release opioids, few studies have directly 
compared reward effects or misuse-related outcomes in 
persons prescribed different opioids or different for­
mulations of a specific opioid for pain. One such 
study found no significant difference in misuse among 
patients receiving short-acting hydrocodone and others 
taking longer acting methadone (Manchikanti et al., 
2005). The theoretical advantages of long-acting opi­
oids, therefore, must be weighed against other clinical 
indications. For example, persons who experience inter­
mittent severe pain may do better with intermittent 
short-acting opioids to cover periods of pain, rather than 
long-acting medications that would provide continu­
ous opioid receptor stimulation even in the absence of 
pain. 
Most controlled-release opioids can have immedi­
ate-release effects through chewing, crushing, snorting, 
or extracting and injecting. Most persons who use pre­
scription opioids to get high do, in fact, alter them in 
some way (Passik et al., 2006a, 2006b). Currently, many 
pharmaceutical companies are pursuing abuse-resistant 
formulations, though it is not likely that any system will 
be entirely abuse-proof. 
If short-acting opioids are used for intermittent pain, 
or with a longer acting medication for incident or crescendo 
pain, there may be advantages to providing these drugs 
on the basis of timing or activity rather than perceived 
pain severity. This practice may serve both to preempt 
pain and to avoid pairing the subjective experience of 
pain with a potentially reinforcing reward. Theoretically, 
such a pairing might increase the experience of pain, jus­
tifying increased opioid dosing in persons vulnerable to 
addiction or addiction relapse and leading to a cycle of 
increasing pain and increasing opioid use and distress 
(Højsted et al., 2006). 
In time-contingent dosing, a patient who rou­
tinely develops pain in the afternoon and evening, for 
example, might receive a dose of a short-acting opioid 
at noon and 5 p.m. only. In activity-contingent dosing, 
someone who has unmanageable pain in association with 
certain valued activities, such as sitting on hard wooden 
pews through a church service, might be instructed to 
take medication 30 minutes before the activity. 
Although concerns regarding drug reward may be 
relevant for persons at risk for opioid misuse or addic­
tion, such concerns should not deter effective and imme­
diate treatment when opioids are required for relief of 
significant acute pain. The long-term outcome of addic­
tion is not likely to be strongly affected by the use of the 
indicated medications in the short term (Ballantyne, 
2007). 
Differential Diagnosis of Opioid Misuse in Pain 
Treatment 
Patients misuse opioids for a variety of reasons that are 
associated with a wide range of implications (Table 3). 
It is important to distinguish clinically between differ­
ent causes of opioid misuse in order to address each case 
appropriately. The most common cause, probably, is 
simply misunderstanding how opioids are supposed to 
be used; clear written instructions can reduce this type 
of misuse. Patients may misuse opioids prescribed for 
pain to obtain relief from depressed feelings, anxiety, 
insomnia, or discomforting memories; these patients 
usually will have a greater benefit from more specific 
treatments. Patients who have become physically depend­
ent on opioids provided for pain may continue to use 
the drugs once the pain has resolved in order to avoid CLINICAL PERSPECTIVE—OPIOID THERAPY OF PAIN • 17 
TABLE 4. Applicability of DSM-IV-TR Diagnostic Criteria for Addiction to Patients Receiving Opioid Analgesia
 
CRITERION 
Tolerance 
Physical dependence/withdrawal 
Used in greater amounts or longer than intended 
Unsuccessful attempts to cut down or discontinue 
Much time spent pursuing or recovering from use 
Important activities reduced or given up 
Continued use despite knowledge of persistent 
physical or psychological harm 
APPLICABILITY 
Limited—tolerance is expected with prolonged analgesic use 
Limited—dependence is expected with prolonged regular analgesic use 
Limited—emergence of pain may demand increased dose or prolonged use 
Limited—emergence of pain may deter dose taper or cessation 
Limited—difficulty finding pain treatment may drive time spent seeking analgesics 
Valid criterion—activity engagement is expected to increase, not decline, with pain 
treatment 
Valid criterion—no harm is anticipated from analgesic opioid use for pain 
Abbreviation: DSM-IV-TR, Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (American Psychiatric Association, 2000). 
withdrawal symptoms; tapering of opioids can usually 
eliminate dependency without significant withdrawal 
distress. 
Patients sometimes exhibit distress and engage in 
behaviors aimed at obtaining more medication because 
their pain treatment is inadequate (Weissman and Had­
dox, 1989). This scenario has been called “pseudoad­
diction,” because it is easy to misinterpret the behaviors 
as indications of addiction rather than as reflections of 
their true underlying cause—a desire for analgesia (Weiss­
man and Haddox, 1989). The solution is to provide ade­
quate pain control, with or without opioids. 
A subset of patients who have a biogenetic vulner­
ability and who use opioids electively in a manner that 
induces euphoria will trigger addiction. This leads to 
continued compulsive use of opioids in a potentially 
self-destructive manner that poses significant personal 
risk. A final type of opioid misuse occurs when indi­
viduals divert opioids from therapeutic channels to share 
or sell them for recreational use, for treatment of untreated 
pain in others, or for financial gain. Such diversion cre­
ates a significant public health risk. 
Incidence of Addiction in Pain Treatment 
The actual rate of occurrence of opioid addiction in the 
course of opioid therapy for pain is uncertain, as no stud­
ies have examined this issue prospectively. Most studies 
that measure substance misuse have excluded persons 
with addictive disorders (Furlan et al., 2006).  
Some studies suggest that a relatively high percent­
age of persons treated for opioid addiction first took the 
drugs in the course of pain treatment. For example, a 
recent study (Passik et al., 2006a) found that 47 percent 
(51 of 109) of persons presenting for treatment of 
oxycodone addiction had their first exposure to opioids 
through a prescription for pain, and 31 percent of this 
subgroup had prior histories of problems with alcohol 
or another substance. This study did not comment on 
the participants’ biogenetic risks as reflected in their fam­
ily histories of addiction and thus shed no light on whether 
these apparent de novo addictions occurred in the pres­
ence or absence of identifiable biogenetic risk. No case 
reports have been identified of patients with no known 
family or personal risk factors presenting with de novo 
addiction to opioids related to use of prescription opi­
oids for pain, though it certainly may occur. 
Studies of the incidence of addiction occurring in 
the context of pain treatment have been variable in qual­
ity and methodology, and have tended to examine a wide 
spectrum of “aberrant drug behaviors” rather than clear 
diagnoses of addiction. The prevalence of identified mis­
use of opioids that are prescribed for pain varies widely 
in different studies, from 1 to 38 percent (Adams et al., 
2001; Ives et al., 2006; Katz and Fanciullo, 2002; Michna 
et al., 2007). The etiology of addiction likely involves 
an interplay between opioids’ reward effects; the indi­
vidual’s biogenetic vulnerability; and modulatory fac­
tors such as the presence of pain, stress, and the psy­
chosocial context of use (Hurd, 2006; Kahan et al., 2006). 
Identification of Addiction in Pain Treatment 
Patients who use opioids on a long-term basis for the 18 • ADDICTION SCIENCE & CLINICAL PRACTICE—JUNE 2008 
TABLE 5. Criteria Suggestive of Misuse or Addiction in Patients With Pain
 
ASAM-APS-AAPM BEHAVIORAL CRITERIA 
Impaired control over use, compulsive use 
Continued use despite harm due to use 
Preoccupation with use, craving 
EXAMPLES OF SPECIFIC BEHAVIORS IN OPIOID THERAPY OF PAIN 
Frequent loss/theft reported, calls for early renewals, withdrawal noted at appoint­
ments 
Declining function, intoxication, persistent oversedation 
Nonopioid interventions ignored, recurrent requests for opioid increase/com­
plaints of increasing pain in absence of disease progression despite titration 
The American Society of Addiction Medicine (ASAM), American Pain Society (APS), and American Academy of Pain Medicine (AAPM) define addic­
tion as a primary, chronic, neurobiological disease with genetic, psychosocial, and environmental factors influencing its development and manifes­
tations characterized by one or more of the behaviors listed above (ASAM, 2001). 
treatment of pain can easily meet five of the seven cri­
teria for substance dependence listed in the Diagnostic 
and Statistical Manual of Mental Disorders, 4th Edition, 
Text Revision (DSM-IV-TR; American Psychiatric Asso­
ciation, 2000) without manifesting the craving or behav­
iors that most addiction professionals regard as the core 
phenomena of addiction (Savage, 1993; Sees and Clark, 
1993; Table 4). Thus, when DSM-IV-TR criteria are 
used to assess for addiction in the context of pain, cli­
nicians must look for two critical criteria: (i) important 
functions or valued activities given up because of drug 
use, and (ii) continued use despite knowledge of per­
sistent physical or psychological harm because of use. 
ASAM, the American Pain Society, and the Ameri­
can Academy of Pain Medicine have developed a defi­
nition of addiction that reflects current clinical and sci­
entific understanding and facilitates assessment for 
addiction in diverse medical contexts, including pain 
treatment (Table 5). The definition lists specific behav­
ioral indicators whose presence may prompt further 
assessment for addiction in the context of pain treat­
ment. Many patients with pain who use opioids as a 
component of care will demonstrate one or more of these 
behaviors from time to time for reasons not related to 
addiction, but a persistent pattern of the behaviors sug­
gests the need for a fuller evaluation. 
The patient who is prescribed opioids for pain and 
who reports reasonably sustained pain control; demon­
strates improving or stable function; participates in other 
recommended evaluations or treatments; discusses the 
need for dose increases at regularly scheduled appoint­
ments; has no, or rare, issues with prescription; and 
exhibits no evidence of other drug or alcohol misuse is 
not likely to be addicted to opioids. However, persons 
who divert medications for sale may sometimes present 
as model patients. 
Clinicians must be vigilant in looking for patterns 
of behavior that may suggest diversion. These include 
known contact with a drug-using population, inability 
to produce the remainder of a partially used prescrip­
tion when asked, noncompliance with other treatment 
recommendations, preference for drugs with a high street 
value, preference for nongeneric drugs, and negative 
urine screens when the drug should be detectable in the 
urine based on dosage and pharmacology. 
Clinical Management of Opioids in Persons With 
Substance Use Problems 
Addiction professionals can make valuable contribu­
tions to safe and desirable outcomes when individuals 
in their care receive opioids as a component of treatment 
for acute or chronic pain. The addiction professional’s 
role varies in different settings but often includes pro­
viding support for recovery and helping patients mini­
mize their risk of misusing medications through cogni­
tive, behavioral, and other strategies. Cognitive-behavioral 
and Twelve-Step approaches may also be helpful in the 
management of pain per se—sometimes directly improv­
ing pain control and at other times helping to reduce 
anxiety and fears that might otherwise exacerbate per­
ceptions of pain (Turner, Holtzman, and Mancl, 2007). 
An understanding of the principles of opioid therapy of 
pain, when integrated with the clinician’s existing coun­
seling skills, makes a good basis for assisting patients 
in pain management. 
Opioids in Acute Pain 
Principles of Care. When significant pain can be antici­
pated, such as after elective surgery or with intermittent 
relapsing pain syndromes (e.g., sickle cell anemia or pan­
creatitis), it is helpful for patients with known addictive 
disease or with physical dependence on licit or illicit opi­ 
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oids to develop a pain treatment plan in advance and to 
document this plan in the medical record. The objec­
tives are to ensure that addiction or physical depend­
ence will be addressed as a co-occurring medical issue, 
that issues such as tolerance and increased medication 
requirements will be appropriately accommodated, and 
that the patient will be treated respectfully. 
Several key principles guide effective opioid therapy 
of acute pain in individuals with physical dependence 
on opioids: 
• The patient’s established daily doses of chronically 
used opioids will not provide analgesia for additional 
acute pain, and additional analgesia, either opioid 
or nonopioid, must be provided; 
• Persons who are physically dependent on opioids usu­
ally also have tolerance and require higher doses at 
more frequent intervals than nondependent persons; 
• Prescribing scheduled, long-acting, or continuous opi­
oids, while reserving the use of pro re nata (prn) med­
ication primarily for dose titration, provides analgesia 
and avoids compelling the patient to request opioids 
frequently, which may be misinterpreted as drug 
seeking; 
• For individuals in recovery from addiction, intensifi­
cation of recovery activities supports safe use of thera­
peutic opioids and may reduce the risk that medical 
challenges and opioid therapy will trigger relapse; and 
• In periods of medical challenge (e.g., illness, surgery, 
trauma), patients with active addiction may be espe­
cially amenable to entering addiction treatment. 
Methadone-Maintained Patients. Clinical consensus 
holds that patients receiving methadone maintenance 
treatment (MMT) of addiction should generally con­
tinue their daily dose of methadone and receive a dif­
ferent medication for acute pain (Scimeca et al., 2000). 
This practice keeps the purpose of each medication clear 
and allows simple tapering of the pain medication as 
acute pain resolves. In addition, there have been case 
reports of opioid withdrawal upon cessation of methadone 
and substitution of other opioids. The reasons for this 
phenomenon are unclear but may be related either to 
methadone’s putative action on a broad spectrum of mu 
subreceptors or to its full agonist properties (Inturrisi, 
2005). Although methadone can be titrated for acute 
pain, doing so requires expertise and careful patient mon­
itoring, because the medication’s slow onset and long 
half-life not only make it difficult to titrate rapidly 
and effectively for pain, but also create a potential for 
unexpected high blood levels and overdose. 
Pain treatment providers should confirm the patient’s 
daily maintenance dose of methadone with his or her 
treatment program. If this is not possible, the physician 
should prescribe a quarter of the reported regular daily 
dosage at 6-hour intervals with observation for sedation 
to ensure safety, as some maintenance doses may be lethal 
in less tolerant patients. If intravenous dosing of methadone 
is required, it should be given at half of the usual oral 
dosage. 
Buprenorphine-Maintained Patients. Strategies for 
managing acute pain in individuals taking buprenor­
phine for the treatment of addiction are emerging as 
experience accumulates. Buprenorphine binds avidly 
to opioid receptors and thus tends to block the action 
of other opioids that may be provided for pain. As a 
result, it is difficult, though not impossible, to obtain 
analgesia by adding another opioid to buprenorphine. 
In addition, buprenorphine has kappa opioid receptor 
antagonist activity that may interfere with the actions 
of other opioids (Vadivelu and Hines, 2007). When 
individuals being treated with buprenorphine face sur­
gery or other predictably pain-generating procedures, 
it is often advisable to discontinue buprenorphine a few 
days beforehand. Carefully dosed methadone can be 
added if withdrawal symptoms emerge after the patient 
stops taking buprenorphine or if continued opioid main­
tenance therapy is needed to block craving while wait­
ing for surgery. 
If a patient on buprenorphine develops pain requir­
ing opioid therapy owing to an accident or other unex­
pected event, mu opioids can usually be aggressively 
titrated to sufficiently high doses to overcome the 
buprenorphine blockade. The intravenous use of an opi­
oid such as fentanyl, which also binds very tightly to mu 
opioid receptors, is often recommended. Opioid titra­
tion for acute pain in this setting should be done by an 
experienced clinician with an intravenous catheter; an 
opioid antagonist such as naloxone should be on hand, 
and the patient should be closely monitored. 
Alternatively, a patient’s low maintenance dose of 
buprenorphine (e.g., 2 to 8 mg per day) can sometimes 
be increased and given at 6-hour intervals to control 
pain. However, because buprenorphine doses of 16 to 
32 mg per day saturate the mu receptors while only par­
tially activating them, buprenorphine’s analgesic effect 
may have a ceiling. It is not clear whether doses higher 
than 16 to 32 mg per day will control more severe pain. 
Understanding of the analgesic properties of buprenor­
phine is still evolving. 
Intensification 
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initiating 
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opioid therapy 
for chronic 
pain. 
Opioids in Chronic Pain 
Some experts suggest that when opioids are a neces­
sary component of chronic pain treatment, a set of uni­
versal precautions be used in managing all patients. The 
rationale for this recommendation parallels that for the 
use of universal precautions in infectious disease settings: 
The risk that an individual patient will misuse opioids 
cannot be reliably predicted; the misuse of opioids has 
potentially serious consequences for both the patient 
and the prescriber; and applying precautions only to 
selected patients risks stigmatizing those patients. There­
fore, it is argued that, for all patients, care providers 
should: 
• Conduct a careful assessment guided by a differential 
diagnosis of the pain; 
• Assess psychological and substance use issues; 
• Obtain informed consent for treatment; 
• Reach a clear treatment agreement; 
• Set up a trial treatment period with clear goals; 
• Assess and periodically reassess pain level (Gourlay, 
Heit, and Almahrezi, 2005), function, and other salient 
issues; and 
• Document care thoroughly. 
Most clinical experts and regulatory boards agree 
that it is important to screen all patients for risk of 
opioid misuse before initiating long-term opioid ther­
apy for chronic pain (ASAM, 2001). Standard assess­
ment of substance use history, when performed in med­
ical settings, most often includes questions about past 
and present alcohol, tobacco, and street drug use, includ­
ing treatment, as well as screening with “cutting down, 
annoyance by criticism, guilty feeling, and eye-openers” 
(CAGE), Drug Abuse Screening Test (DAST), or other 
common instruments (Brown and Rounds, 1995). 
A number of screens to assess the risk of medication 
misuse in pain treatment settings are being developed 
(Akbik et al., 2006; Friedman, Li, and Mehrotra, 2003). 
Two that appear promising are the Screener and Opioid 
Assessment for Patients in Pain, which has been validated 
as a 14- and 20-question screen and is now undergoing 
testing in a shorter form, and the Opioid Risk Tool, a 
user-friendly, five-question screen that discriminates well 
between high- and low-risk patients (Webster and Web­
ster, 2005). An important caveat concerning these 
tools is that none has been specifically validated for 
use in populations with substance use disorders. During 
treatment for pain, clinicians can use measures such as 
the Addiction Behaviors Checklist to track behaviors 
of concern (Wu et al., 2006). 
Adapting the Structure of Care to Match Risks 
When a risk of opioid misuse is perceived, individual­
izing and tightening the structure of clinical care beyond 
universal precautions may enhance safety. In this situ­
ation, it is helpful to think in terms of five domains of 
structure: 
• Setting of care (primary versus specialty care, clinical 
care team membership); 
• Selection of treatment (risk/benefit assessment of spe­
cific medications and treatments); 
• Supply of medications (controls on and amounts of 
medications dispensed); 
• Supports for recovery (implementation and docu­
mentation of recovery activities); and 
• Supervision and monitoring (frequency of visits, tox­
icology screens, pill counts, other). 
Although there is some overlap in these areas, atten­
tion to each ensures that the clinician has thought through 
the best options of care for the particular patient. 
Setting of Care 
Some patients with pain are best managed in a pri­
mary care setting with support from specialists; others 
are best managed in a specialty care setting by a clini­
cian with specific skills in an area of need, for example, 
a pain specialist, addiction specialist, or psychiatrist 
(Gourlay, Heit, and Almahrezi, 2005). There are advan­
tages and disadvantages to each setting. Primary care 
providers tend to have broader and more longitudinal 
knowledge of the patient and are in a better position 
to integrate pain care with other medical care issues. Spe­
cialists tend to have a greater depth of knowledge and 
expertise in the management of a particular aspect of the 
patient’s medical care and may provide better manage­
ment when a particular problem is prominent, such as 
addiction or psychiatric instability. 
Many variables may contribute to the determination 
of the best setting of care for an individual patient. No 
formula can dictate which professional should manage 
a particular clinical pain problem, but the consideration 
of a number of variables may be helpful in decision mak­
ing (Table 6). The most appropriate management set­
ting may change as the patient’s presentation changes. 
Selection of Treatment 
The selection of pain treatments, as with most medical 
treatments, is usually based on a determination of which 
would likely provide the most benefit for the patient 
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TABLE 6. Proposed Algorithm for Determining the Appropriate Setting for Pain Management
 
Clear, straightforward etiol­
ogy of pain 
No history of psychiatric 
disorder 
No history of substance 
abuse or addiction 
Good social support 
Rich work or avocational life 
Uncertain etiology, but some phys­
iological clues or a suggestive pat­
tern of pain 
Stable, well-compensated psychi­
atric disorder 
In recovery or history of major 
substance abuse 
Some social discord or challenging 
social net 
Some engagement with meaningful 
activities 
Etiology unknown, no physiological 
clues, no familiar pattern, or complex 
treatment needs 
Psychiatric instability 
Active addiction, current illicit use 
Isolated, major social distress, destruc­
tive associates 
No satisfying work, recreation, or other 
activities 
GENERALIST CARE  SPECIALIST CARE 
Pain Etiology 
Psychiatric Disorder 
Addiction 
Social Support 
Activity 
Engagement 
CLINICAL PARAMETER 
provider’s skills and clinical opinions are also important 
factors that shape treatment selection. In a patient with 
relapsing opioid addiction, cognitive limitations, or cer­
tain psychiatric disorders, opioid analgesics may repre­
sent a greater risk than for persons without these con­
ditions. In such patients, a treatment that is relatively 
invasive or expensive might be preferable early in the 
course of pain treatment, when other patients might 
receive instead a trial of opioid therapy. For example, 
patients with unilateral radiculopathy usually receive a 
trial of pharmacological therapy, including opioid ther­
apy, prior to consideration of spinal cord stimulation 
(SCS), as the latter is considerably more invasive and 
costly. However, SCS might justifiably be tried first when 
a patient has relapsing opioid addiction, because the 
addiction shifts the risk/benefit/cost balance. Similarly, 
knowing that a patient experiences reward from short-
acting opioids (referred to by one recovering patient as 
“dancing with an old lover”) could warrant the prompt 
choice of slow-onset, long-acting opioids, although they 
cost more and typically are given only after the shorter 
acting opioids fail to control pain. 
Supply of Medications 
Making opioids available in quantities that relieve 
pain but do not invite misuse is a key factor in success­
ful opioid therapy of pain in persons with substance use 
problems. The number of units of opioid medications 
available to the patient and the frequency with which 
they are dispensed are two variables that can be con­
trolled. 
In current practice, patients commonly receive a 
month’s supply of analgesic opioids, and some clinicians 
provide stable patients who have no detected risks with 
up to a 3-month supply. For persons who have addic­
tive disorders or tend to overuse medications for other 
reasons, however, it is often prudent to dispense smaller 
quantities of medications more frequently, for example, 
weekly or even daily. This practice can help a patient 
avoid overuse (“a little extra won’t hurt and may help”), 
because it is easier to see that taking two of seven one-
a-day tablets will deplete the supply before week’s end 
than it is to see that taking five rather than the prescribed 
four tablets per day will exhaust a supply of 120 before 
month’s end. 
Frequent dispensing of small doses can also preserve 
safety by ensuring that persons prone to harmful mis­
use do not have a potentially lethal supply available. 
Applying a signed and dated transdermal fentanyl patch 
in the physician’s office every 72 hours may be a helpful 
procedure for some patients considered at risk. How­
ever, it is important to note that all long-acting med­
ications can be altered to cause release of the full dose 
immediately, and injection or transmucosal use of the 
opioid contained in any 3-day fentanyl patch could be 
lethal to most persons. In the final analysis, the only 
method that fully protects a patient who is at risk for 
major overuse is keeping the total dose dispensed sub­
lethal. 
Frequent dispensing can be done by a pharmacy, a 
clinician’s office, or a trusted surrogate, such as a family 
member. In the last instance, care must be taken to avoid 
potential resentment and conflict over the surrogate care­
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Addiction 
professionals 
provide an 
important 
service by 
supervising 
the recovery 
plan while 
patients are 
using opioids 
for pain. 
Supports for Recovery 
Many persons who are recovering from an addictive dis­
order and require opioids for pain treatment benefit from 
active cultivation of their recovery. What constitutes a 
meaningful array of recovery activities varies between 
individuals but may include, for example, attendance at 
self-help meetings, close interaction with a sponsor, work 
with a counselor, or active participation in a faith 
community. Addiction professionals may provide an 
important service to patients and their pain treatment 
providers by recommending ways to enrich recovery and 
by supervising the recovery plan while patients are using 
opioids for pain. Persons with other conditions that may 
put them at risk for misuse of medications, such as psy­
chiatric disorders or cognitive impairment, generally 
will benefit from engagement of appropriate profes­
sionals to assist in management of or accommodation 
to their illness. 
Individuals with relapsing opioid addiction who 
require opioids for severe chronic pain sometimes 
benefit from concurrent MMT. Methadone provides a 
stable background dose of opioids that checks craving, 
blocks the high of other opioids, and provides physio­
logical homeostasis. However, because methadone’s anal­
gesic effects usually last only 6 to 8 hours, once- or twice-
daily dosing does not usually meet analgesic needs unless 
the dose is titrated very high. Therefore, comanagement 
by a pain treatment provider who provides analgesic opi­
oids and by an MMT clinic that provides once-daily or 
twice-daily split doses of methadone is the best option 
for some patients who require MMT stabilization to be 
able to safely use opioids for analgesia. 
Although buprenorphine in sublingual form has not 
been approved for pain treatment in the United States, 
anecdotal evidence and evolving clinical trials suggest a 
possible emerging role for buprenorphine as an anal­
gesic for chronic pain in individuals with opioid addic­
tion. More study is needed to shape guidelines for its use 
in this context. 
Supervision of Care 
Patients who receive opioid therapy for pain should be 
seen by their prescribing clinician on a regular basis 
for monitoring of their pain, functional status, mood, 
use of medications, and general well-being (Atluri et al., 
2003). Typical intervals for visits vary from once a week 
to once every 3 months, with monthly intervals being 
most common. Unstable patients or those with more 
complex problems should be seen more often, while sta­
ble patients with straightforward pain problems may be 
seen less often. In rare cases, daily contact with a clini­
cian is appropriate. 
Toxicology testing, usually urine drug screening, is 
increasingly routine as part of the supervision of patients 
using opioids on a long-term basis and may actually pro­
mote recovery in persons with addiction. For persons 
with no apparent risks for medication misuse, toxicol­
ogy testing is often done randomly on an annual basis. 
For persons at higher risk, testing may be done as 
often as weekly, especially during periods of high stress. 
Recent work (Acosta and Haller, 2006; Cheatle and 
Gallagher, 2006; Wiedemer et al., 2007) has suggested 
that patients with aberrant behaviors and even with ongo­
ing substance abuse can obtain safe and effective pain 
management if their care plan includes appropriate struc­
tural components and active interventions to address 
substance abuse. In a U.S. Department of Veterans Affairs 
facility, Gallagher and colleagues (Wiedemer et al., 2007) 
utilized consultations with clinical pharmacists, signing 
of second chance agreements, and simple limit-setting 
interventions (e.g., more frequent visits, limited sup­
plies of opioids, urine toxicology screening) in patients 
manifesting aberrant behaviors. Of those referred for 
this consultation, 45 percent were able to remain in pain 
management and obtained reasonable control over their 
behavior, while about 38 percent self-discharged. The 
Haller group (Acosta and Haller, 2006) demonstrated 
that a set of highly intensive psychological interventions, 
including adherence monitoring, motivational tech­
niques, and cognitive-behavioral techniques, when added 
to a methadone-based pain management program, led 
to a diminution in abuse of nonprescribed opioids and 
a trend toward decreases in nonopioid drug abuse in a 
group of active drug abusers with chronic pain. 
Discontinuation of Opioid Therapy 
Opioid therapy may be discontinued if it no longer 
achieves its goals of improved pain, stable or improving 
function, and enhanced quality of life; if it cannot be 
structured to maintain the safety of the patient because 
of addictive use; if other concerns, such as medication 
diversion, are documented; or if pain resolves. In these 
cases, it is helpful to have obtained, at the start of ther­
apy, the patient’s written assent to a list of conditions for 
continuing and discontinuing opioid therapy. Opi­
oids should be tapered to avoid withdrawal and a rebound 
increase in pain, and other interventions should be used 
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occur. If addiction is identified, treatment for addiction 
should be initiated or intensified. 
ROLES FOR ADDICTION PROFESSIONALS IN 
PAIN TREATMENT 
Treatment of pain, especially chronic pain, in an indi­
vidual with a co-occurring addiction or other substance 
use problem is often time-consuming and stressful for 
primary care physicians and pain treatment specialists. 
In this situation, most will welcome an informed addic­
tion professional as a partner in the patient’s care. Depend­
ing on the skills of the addiction professional, he or 
she may: 
• Provide cognitive and behavioral interventions that 
support both pain management and addiction recov­
ery; 
• Participate with the treatment team to develop a safe 
and effective medication management plan when opi­
oids are part of treatment; 
• Provide thoughtful, differential assessment of aberrant 
use of opioid medications when it occurs; 
• Provide intervention and treatment for addiction when 
present; 
• Support and monitor recovery; 
• Assist patients who are using a Twelve-Step approach 
to addiction or pain recovery; and 
• Communicate concerns regarding recovery and med­
ication use, working with the pain management team 
to address these concerns effectively. 
CONCLUSION 
Although even the most careful clinical management 
cannot eliminate all risk of opioid misuse, especially in 
persons with histories of drug misuse or addictive dis­
orders, appropriate screening, care in structuring opi­
oid management, and good communication with patients 
and care team members can reduce risk significantly. 
The effective management of pain in patients with a co­
occurring addictive disorder requires a comprehensive 
approach that recognizes the biological, pharmacolog­
ical, social, and psychiatric aspects of substance misuse 
and addiction, as well as practical means to manage risk, 
treat pain effectively, and ensure patient safety. Recent 
data have begun to suggest that pain management can 
proceed effectively and may even be associated with 
decreases in drug abuse in programs that utilize highly 
structured approaches and pay attention not solely to 
either the pain or the addiction, but both. 
Unfortunately, there are very limited data relevant 
to risk assessment in medically ill patients with pain, and 
most data related to the risk of opioid misuse or addic­
tion during long-term opioid treatment of medically 
stable patients with chronic pain are derived from work 
with patients with no history of substance abuse. 
Clinicians must therefore rely on extrapolated knowl­
edge, clinical experience, and careful observation to 
achieve balance in caring for these patients. The expe­
riences of both researchers in this fledgling area and expe­
rienced clinicians suggest that a compassionate and 
humane approach, one that gives pain and addiction 
dedicated attention, can lead to satisfying outcomes even 
for the most challenging of patients. 
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